Pages that link to "Item:Q11181"
← Section 4: COVID-19 treatment by IFN-lambda: Pros and cons (from DOI: 10.1084/jem.20200653) (Q11181)
Jump to navigation
Jump to search
The following pages link to Section 4: COVID-19 treatment by IFN-lambda: Pros and cons (from DOI: 10.1084/jem.20200653) (Q11181):
View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)- COVID-19 and emerging viral infections: The case for interferon lambda (DOI: 10.1084/jem.20200653) (Q10304) (← links)
- Section 1: Introduction (from DOI: 10.1084/jem.20200653) (Q11178) (← links)
- Section 2: IFNs as natural broad-spectrum antivirals (from DOI: 10.1084/jem.20200653) (Q11179) (← links)
- Section 3: IFN-lambda as an antiviral drug (from DOI: 10.1084/jem.20200653) (Q11180) (← links)
- Section 4: COVID-19 treatment by IFN-lambda: Pros and cons (from DOI: 10.1084/jem.20200653) (Q11181) (← links)
- References (from DOI: 10.1084/jem.20200653) (Q11182) (← links)